Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631044 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
A Phase 1 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 387
- Enrollment target
NCT02631044: Completed Phase 1 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
NCT02631044 is a Phase 1 study that has completed, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 387 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (545% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02631044, a Phase 1 study, has completed, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 387 participants
- Enrollment target
Study Summary
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.
Primary Outcome
Physiological parameter
Interventions
- BIOLOGICAL JCAR017 (lisocabtagene maraleucel) single-dose schedule
- BIOLOGICAL JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2016-01-06 |
| Est. Completion | 2024-05-16 |
| Phase | Phase 1 |
What the finished NCT02631044 record still lists
NCT02631044 is an interventional study that assigns participants to a tested intervention. The registered 387 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (545% higher).
The record links to 0 conditions, and to 2 interventions - of which JCAR017 (lisocabtagene maraleucel) single-dose schedule is the first listed.
NCT02631044 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02631044 about?
NCT02631044 is a clinical study titled "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)". This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We wi...
What is the current status of trial NCT02631044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 387 participants. The study started on 2016-01-06. Estimated completion is 2024-05-16.
What interventions are being tested in trial NCT02631044?
The interventions under investigation include: JCAR017 (lisocabtagene maraleucel) single-dose schedule (BIOLOGICAL), JCAR017 (lisocabtagene maraleucel) 2-dose schedule (BIOLOGICAL).
Who is sponsoring clinical trial NCT02631044?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02631044's enrollment target sits among peer trials
387 79th of 2000 higher than 1,920 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03761108 · 387 participants · Phase 1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- NCT05572632 · 387 participants · NA
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
- NCT06917079 · 387 participants · Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI